Spots Global Cancer Trial Database for HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma

Official Title: A Phase 1b Trial of AR-42 With Pomalidomide in Relapsed Multiple Myeloma

Study ID: NCT02569320

Conditions

Recurrent Plasma Cell Myeloma

Interventions

Dexamethasone

HDAC Inhibitor AR-42

Laboratory Biomarker Analysis

Pomalidomide

Study Description

Brief Summary: This pilot phase I trial studies the side effects and best dose of histone deacetylase (HDAC) inhibitor AR-42 (AR-42) when given together with pomalidomide in treating patients with multiple myeloma that has returned after a period of improvement. HDAC inhibitor AR-42 may work to stop cancer growth by blocking an enzyme needed for cell growth. Pomalidomide is a drug used in chemotherapy that works to stop the growth of cancer cells by causing them to die. Giving HDAC inhibitor AR-42 together with pomalidomide may cause patients to respond better to treatment.

Detailed Description: PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose, safety and efficacy of AR-42 in combination with pomalidomide in relapsed multiple myeloma (MM) patients. SECONDARY OBJECTIVES: I. To determine time to progression (TTP). II. To determine overall survival (OS). OUTLINE: This is a dose-escalation study of HDAC inhibitor AR-42 and pomalidomide. Patients receive pomalidomide orally (PO) daily on days 1-21, dexamethasone PO twice weekly (BIW) or thrice weekly (TIW) weeks 1-3, and HDAC inhibitor AR-42 PO BIW or TIW on weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for at least 30 days.